Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom on Track for June Launch of Prenatal Test

NEW YORK (GenomeWeb News) – Sequenom announced last night that it is on track to launch this June its non-invasive, RNA-based, SEQureDx test for assessing fetal aneuploidy in maternal blood.

Sequenom President and CEO Harry Stylli said in a statement that the company has completed R&D studies on its RNA-based trisomy 21 detection test. He said the company will now transfer the technology to the Sequenom Center for Molecular Medicine for the remaining development and validation steps prior to the June launch.

The announcement follows the completion of a prospective clinical trial that the company says yielded positive data. The firm tested 459 samples using Sequenom's RNA-based test and reportedly detected all eight first trimester Down syndrome samples with no false positives or negatives, as well as 14 of 15 second trimester Down syndrome samples. One second trimester Down syndrome sample could not be resolved using the test, but was verified by other methods, and another second trimester sample yielded a false positive result.

Sequenom also is pursuing a DNA-based approach for simultaneously testing for trisomy 21 (Down syndrome) and other trisomies, such as trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome).

Earlier this week, Artemis Health announced that it licensed co-exclusive worldwide rights from Stanford University to develop a non-invasive, DNA-based test of its own for detecting fetal trisomies in maternal blood. Fluidigm holds co-exclusive rights to the same DNA-based approach, developed in Stephen Quake's lab at Stanford University.

After seeing its shares fall to as low as $19.95 during the day, Sequenom's shares closed up 1 percent at $22.73 on the Nasdaq.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.